US20010008944A1 - Method for preparing cycloheptimidazoles - Google Patents
Method for preparing cycloheptimidazoles Download PDFInfo
- Publication number
- US20010008944A1 US20010008944A1 US09/805,516 US80551601A US2001008944A1 US 20010008944 A1 US20010008944 A1 US 20010008944A1 US 80551601 A US80551601 A US 80551601A US 2001008944 A1 US2001008944 A1 US 2001008944A1
- Authority
- US
- United States
- Prior art keywords
- compound
- compounds
- reaction
- lower alkyl
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C1=C(OC)CCCCC1=O Chemical compound *C1=C(OC)CCCCC1=O 0.000 description 6
- UKSFUXDYVAJVHE-UHFFFAOYSA-N CC1=CC=CC=C1C1=CC=C(CN2C(C)=NC3=C2C(=O)CCCC3)C=C1 Chemical compound CC1=CC=CC=C1C1=CC=C(CN2C(C)=NC3=C2C(=O)CCCC3)C=C1 UKSFUXDYVAJVHE-UHFFFAOYSA-N 0.000 description 1
- RAMLXABWXGXRGU-UHFFFAOYSA-N CC1=NC2=C(N1)C(=O)CCCC2 Chemical compound CC1=NC2=C(N1)C(=O)CCCC2 RAMLXABWXGXRGU-UHFFFAOYSA-N 0.000 description 1
- JMQKLQMGERJBDR-UHFFFAOYSA-N COC1=CC=C(C2=C(Cl)C(=O)CCCC2)C=C1.COC1CCC=C(Cl)C(=O)C1.O=C1CCCCC=C1Cl Chemical compound COC1=CC=C(C2=C(Cl)C(=O)CCCC2)C=C1.COC1CCC=C(Cl)C(=O)C1.O=C1CCCCC=C1Cl JMQKLQMGERJBDR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
- C07C45/511—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition involving transformation of singly bound oxygen functional groups to >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/703—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups
- C07C49/717—Unsaturated compounds containing a keto groups being part of a ring containing hydroxy groups a keto group being part of a seven- to twelve-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
Definitions
- This invention relates to novel key intermediates, 3-hydoxy-2-halocycloheptenones and 3-alkoxy-2-halocycloheptenones, which are useful for the synthesis of drug medicine.
- this invention relates to preparation of the key intermediates of novel cycloheptimidazole derivatives that have angiotensin II receptor antagonistic activities and are therefore useful for the treatment of hypertension, congestive heart failure and so on.
- Cyclohepta-1,3-dione (8) can be obtained by known method.
- the reaction condition is anhydrous. 2) Et 2 Zn is subject to autoignition. Moreover, the objective compound (3) is not obtained under several conditions for halogenation of the compound (8), and dihalogenation reaction occurs and 2,2-dihalo-1,3-cycloheptandione (9) is obtained as a main product.
- This invention relates to novel key intermediates, useful for the preparation of the cycloheptanoides such as cycloheptimidazole derivatives which are useful for the synthesis of medicine and presents its use for the preparation of the cycloheptimidazoles.
- the compounds of the present invention are compounds of general formula (1):
- R 1 is hydrogen atom or lower alkyl group
- X is bromine atom or chlorine atom.
- “lower” means straight or branched chain from C 1 or C 5 .
- the compounds of general (1) such as 3-hydroxy-2-halocycloheptenone and 3-alkoxy-2-halocycloheptenone can be obtained from 1 ,2-bis(trialkylsilyloxy)cyclohexene (2) which is easily available in a few steps.
- the synthetic method for preparation of these compounds is shown as follows.
- R 2 and R 3 are lower alkyl group
- X is bromine atom or chlorine atom.
- the compound (13) is obtained by the reaction of 1,2-bis(trialkylsilyloxy)cyclohexene (2) with dihalocarbene which is prepared from chloroform or bromoform in the presence of base such as potassium tert-butoxide.
- base such as potassium tert-butoxide.
- two reactions, namely a ring chlorination and expansion proceed in one pot and the compound (13) is subjected to ring expansion to obtain the compound (3) without isolation.
- This reaction is carried out in an inert organic solvent, such as, heptane, hexane and pentane, at from ⁇ 40° C. to room temperature.
- compound (3) is reacted with alcohol such as methyl alcohol or ethyl alcohol in the presence of acid catalyst to give 3-alkoxy-2-chlorocycloheptenone (compound (4)) or 3-alkoxy-2-bromocycloheptenone.
- Hydrochloric acid, sulfonic acid, methanesulfonic acid, p-methylbenzene sulfonic acid and ion exchange resin can be used as an acid catalyst.
- This alkylation is also carried out in the presence of orthoester such as trimethyl orthoformate. In general, this reaction is carried out at a temperature of from 0° C. to room temperature.
- 1,2-Bis(trialkylsilyloxy) cyclohexene (2) can be prepared according to the reported methods (K. Rublmann., Synthesis, 236, 1971).
- Compounds of general formula (4) are as follows: 3-Methoxy-2-chlorocycloheptenone, 3-Methoxy-2-bromocycloheptenone, 3-Ethoxy-2-chlorocyclo-heptenone, 3-Ethoxy-2-bromocycloheptenone and so on.
- a compound of general formula (1) can be converted to various cycloheptanoide derivatives.
- the compounds of general formula (5) are obtained by the reaction of compound (1) with alkylamidine hydrochloride in the presence of base.
- the compounds of general formula (5) are useful for the synthesis of cycloheptimidazole derivatives which have angiotensin II receptor antagonistic activities.
- R 1 is hydrogen atom or lower alkyl group
- X is bromine atom or chlorine atom
- R 4 is lower alkyl group
- the compound (1) wherein R 1 is lower alkyl group is reacted with butylamidine hydrochloride in the presence of K 2 CO 3 to give cycloheptimidazole derivatives (5) in which R 4 is n-propyl group.
- 1,4-dioxane or chloroform-H 2 O are preferred as solvent.
- this reaction is carried out at room temperature or under heating conditions.
- the aqueous layer was washed with two portions of ethyl acetate and adjusted to pH 3 using 5% hydrochloric acid solution, followed by extraction with chloroform.
- the organic solution was washed with brine and dried over Na 2 SO 4 , filtered and the solvent was evaporated in vacuo, to give 22 g of the title compound.
- IR cm ⁇ 1 (KBr): 2932, 1653, 1578, 1248, 1224.
- the aqueous solution was acidified to pH 5.0 with 10% hydrochloric acid and extracted with ethyl acetate.
- the organic solution was concentrated, followed by acidification with, ethanol which is saturated by hydrochloric acid, and the solvent was removed in vacuo.
- the residue was recrystallized from ethyl alcohol-diethyl ether to give 3.1 g of title compound.
- novel compounds of this invention are key synthetic intermediates of cycloheptanoido derivatives.
- cycloheptimidazol derivatives can be synthesized by using 3-alkoxy-2-halocycloheptenone easily.
- the compounds of the present invention can be synthesized easily by a short process, and this invention has the advantage that the compounds can be obtained in practical scale with no use of heavy metals and hazardous reagents which present a risk to environmental sanitation.
- This invention relates to novel key intermediates, the cycloheptanoide compounds such as cycloheptimidazole derivatives, and their use for the production method of the cycloheptimidazole derivatives.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
wherein: R1 is hydrogen atom or lower alkyl group, X is bromine atom or chlorine atom; and which are usefull for the preparation of the cycloheptanoides such as cycloheptimidazole derivatives. The compound having formula (1) is obtained in a single pot by the reaction of a trialkylsilylether compound with a dihalocarbene which, in turn, is prepared from the reaction of chloroform or bromoform in the presence of base.
Description
- 1. Field of the Invention
- This invention relates to novel key intermediates, 3-hydoxy-2-halocycloheptenones and 3-alkoxy-2-halocycloheptenones, which are useful for the synthesis of drug medicine. In detail, this invention relates to preparation of the key intermediates of novel cycloheptimidazole derivatives that have angiotensin II receptor antagonistic activities and are therefore useful for the treatment of hypertension, congestive heart failure and so on.
- 2. Description of the Prior Art
- Many compounds containing cyclohept rings possess potent physiological activities. For example, we proposed cycloheptimidazoles of general formula (6) that have angiotensin II receptor antagonistic activities and are therefore useful for the treatment of hypertension or congestive heart failure. (Japanese Patent laid-open Publication 5-320139, 7-149761and 8-73454.)
- (wherein: R5 is hydrogen atom or lower alkyl group, R6 is carboxyl group, tetrazolyl group) However, the synthetic method of the cycloheptaimidazoles, shown in general formula (6), is unfavorable on an industrial scale because of the following reasons.
- 1) The starting material, tropolone is expensive.
- 2) A large number of process steps are needed.
- 3) This procedure is not applicable to a wide range of cycloheptanoid compounds.
-
- (wherein: R2 and R3 is lower alkyl group, X is bromine atom or chlorine atom.) In other words Cyclohepta-1,3-dione (8) can be obtained by known method. First, cyclopropanation of compound (2) in the presence of Et2 Zn and CH2I2 (Simmons-Smith reaction) gives the bicyclic compound (7) (L. Hadjiarapoglou, Synthesis, 525, 1996). Second, ring enlargement of (7) using FeCl3 or periodic acid gives the compound (8) (T. Saegusa, Organic Synthesis 59, 113; M. C. Pirrung, J. Org. Chem. 52, 3606, 1987). Then the halo analogue (3) seems to be prepared in a similar manner as described by R. G. Shepherd (J.Chem. Soc. Perkin Trans. I, 2153,1987), and its etherification affords 2-halo-3-alkoxycyclohept-2-enone(4). However, Simmons-Smith reaction is not useful industrially because of following reasons.
- 1) The reaction condition is anhydrous. 2) Et2Zn is subject to autoignition. Moreover, the objective compound (3) is not obtained under several conditions for halogenation of the compound (8), and dihalogenation reaction occurs and 2,2-dihalo-1,3-cycloheptandione (9) is obtained as a main product.
- Similarly, well-known procedure was not applicable to the synthesis of the compounds (3) and (4). Furthermore, although the compounds (10) (Chem. Abstr. 77, 48038k, 1972 (U.S. Pat. No. 3,658,841)), (11) and (12) (Chem. Abstr. 89, 179583e, 1978 (J. Org. Chem. 43, 4241, 1978)) have already been known, 3-hydroxy-2-halocycloheptenone and 3-alkoxy-2-halocycloheptenone, which are shown as general formula (1), below, are not yet reported and are new compounds.
- Problems to be Solved by the Invention
- This invention relates to novel key intermediates, useful for the preparation of the cycloheptanoides such as cycloheptimidazole derivatives which are useful for the synthesis of medicine and presents its use for the preparation of the cycloheptimidazoles.
- We have explored to find a practical procedure, of wide range usefulness, for cycloheptanoide compounds. Consequently, we found that 3-hydroxy-2-halocycloheptenone and 3-alkoxy-2-halocycloheptenone were the most suitable intermediates and, at the same time, we found the practical synthetic procedure of these intermediates which is scalable for the industrial scale, and this invention was completed.
-
- wherein: R1 is hydrogen atom or lower alkyl group, X is bromine atom or chlorine atom. In this invention, “lower” means straight or branched chain from C1 or C5.
-
- wherein: R2 and R3 are lower alkyl group, X is bromine atom or chlorine atom. Namely, the compound (13) is obtained by the reaction of 1,2-bis(trialkylsilyloxy)cyclohexene (2) with dihalocarbene which is prepared from chloroform or bromoform in the presence of base such as potassium tert-butoxide. Thus, two reactions, namely a ring chlorination and expansion, proceed in one pot and the compound (13) is subjected to ring expansion to obtain the compound (3) without isolation. This reaction is carried out in an inert organic solvent, such as, heptane, hexane and pentane, at from −40° C. to room temperature.
- Above mentioned compound (3) is reacted with alcohol such as methyl alcohol or ethyl alcohol in the presence of acid catalyst to give 3-alkoxy-2-chlorocycloheptenone (compound (4)) or 3-alkoxy-2-bromocycloheptenone. Hydrochloric acid, sulfonic acid, methanesulfonic acid, p-methylbenzene sulfonic acid and ion exchange resin can be used as an acid catalyst. This alkylation is also carried out in the presence of orthoester such as trimethyl orthoformate. In general, this reaction is carried out at a temperature of from 0° C. to room temperature. 1,2-Bis(trialkylsilyloxy) cyclohexene (2) can be prepared according to the reported methods (K. Rublmann., Synthesis, 236, 1971).
- Compounds of general formula (4) are as follows: 3-Methoxy-2-chlorocycloheptenone, 3-Methoxy-2-bromocycloheptenone, 3-Ethoxy-2-chlorocyclo-heptenone, 3-Ethoxy-2-bromocycloheptenone and so on.
- A compound of general formula (1) can be converted to various cycloheptanoide derivatives. For example, the compounds of general formula (5) are obtained by the reaction of compound (1) with alkylamidine hydrochloride in the presence of base. The compounds of general formula (5) are useful for the synthesis of cycloheptimidazole derivatives which have angiotensin II receptor antagonistic activities.
- wherein: R1 is hydrogen atom or lower alkyl group, X is bromine atom or chlorine atom, R4 is lower alkyl group.
- For example, the compound (1) wherein R1 is lower alkyl group is reacted with butylamidine hydrochloride in the presence of K2CO3 to give cycloheptimidazole derivatives (5) in which R4 is n-propyl group. In this reaction, 1,4-dioxane or chloroform-H2O are preferred as solvent. In general, this reaction is carried out at room temperature or under heating conditions.
- To a stirred mixture of 67.6 g of 1,2-bis(trimethylsilyloxy)cyclohex-1-ene and 52.1 g of potassium tert-butoxide in 600 mL of pentane, 25.1 mL of chloroform was added over 0.5 h at −20° C. After an additional 0.5 h at room temperature, 10 mL of 10% hydrochloric acid and 30 mL of water was added. After an additional 1 h at room temperature, the mixture was poured into 200 mL of saturated aqueous NaHCO3. The aqueous layer was washed with two portions of ethyl acetate and adjusted to pH 3 using 5% hydrochloric acid solution, followed by extraction with chloroform. The organic solution was washed with brine and dried over Na2SO4, filtered and the solvent was evaporated in vacuo, to give 22 g of the title compound.
- MS(m/z): 162 (M+2), 160 (M+), 97, 84, 76, 55.
-
- A mixture of 5.0 g of 2-chloro-3-hydroxycyclohept-1-one, 5.0 mL oftrimethyl orthoformate, and 30 mL of methanol was stirred in the presence of IR 120H ion-exchange resin (0.5 g, pre-washed with methanol) at room temperature. After 3 h the mixture was filtered and filtrate was extracted with ethyl acetate. The organic solution was washed with saturated aqueous NaHCO3, brine and dried over Na2SO4, filtered and the solvent was evaporated in vacuo, to give 2.8 g of the title compound.
- MS(m/e): 176 (M+2), 174 (M+), 145, 118,97, 61
- IR cm−1(KBr): 2932, 1653, 1578, 1248, 1224.
-
- A solution of 3.79 of butylamidine hydrochloride and 8.4 g of K2CO3 in 1,4-dioxane, maintained at reflux condition was treated dropwise with a solution of 3.7 g of 2-chloro-3-methoxycyclohept-1-one in 1,4-dioxane. After 2 h the mixture was cooled to room temperature, followed by extraction with ethyl acetate. The organic solution was washed with water, brine and dried over Na2SO4, filtered and concentrated. The crude product was dissolved in toluene, followed by extraction with 10% aqueous NaOH. The aqueous solution was acidified to pH 5.0 with 10% hydrochloric acid and extracted with ethyl acetate. The organic solution was concentrated, followed by acidification with, ethanol which is saturated by hydrochloric acid, and the solvent was removed in vacuo. The residue was recrystallized from ethyl alcohol-diethyl ether to give 3.1 g of title compound.
- MS(m/z): 192 (M—HCl)+, 164,131, 95,67.
-
- Effectiveness of the Invention
- The novel compounds of this invention, 3-hydoxy-2-halocycloheptenone and 3-alkoxy-2-halocycloheptenone, are key synthetic intermediates of cycloheptanoido derivatives. For example, cycloheptimidazol derivatives can be synthesized by using 3-alkoxy-2-halocycloheptenone easily. The compounds of the present invention can be synthesized easily by a short process, and this invention has the advantage that the compounds can be obtained in practical scale with no use of heavy metals and hazardous reagents which present a risk to environmental sanitation.
- This invention relates to novel key intermediates, the cycloheptanoide compounds such as cycloheptimidazole derivatives, and their use for the production method of the cycloheptimidazole derivatives.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/805,516 US6316634B2 (en) | 1998-09-08 | 2001-03-14 | Method for preparing cycloheptimidazoles |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25359598A JP4018816B2 (en) | 1998-09-08 | 1998-09-08 | Cycloheptenone derivative and method for producing the same, and method for producing cycloheptimidazole derivative using the same |
JP10-253595 | 1998-09-08 | ||
JP253595/98 | 1998-09-08 | ||
US09/391,385 US6278027B1 (en) | 1998-09-08 | 1999-09-08 | 3-Substituted-2-halocycloheptenone compounds and a method for manufacturing same |
US09/805,516 US6316634B2 (en) | 1998-09-08 | 2001-03-14 | Method for preparing cycloheptimidazoles |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/391,385 Division US6278027B1 (en) | 1998-09-08 | 1999-09-08 | 3-Substituted-2-halocycloheptenone compounds and a method for manufacturing same |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010008944A1 true US20010008944A1 (en) | 2001-07-19 |
US6316634B2 US6316634B2 (en) | 2001-11-13 |
Family
ID=17253574
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/391,385 Expired - Fee Related US6278027B1 (en) | 1998-09-08 | 1999-09-08 | 3-Substituted-2-halocycloheptenone compounds and a method for manufacturing same |
US09/805,516 Expired - Fee Related US6316634B2 (en) | 1998-09-08 | 2001-03-14 | Method for preparing cycloheptimidazoles |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/391,385 Expired - Fee Related US6278027B1 (en) | 1998-09-08 | 1999-09-08 | 3-Substituted-2-halocycloheptenone compounds and a method for manufacturing same |
Country Status (4)
Country | Link |
---|---|
US (2) | US6278027B1 (en) |
JP (1) | JP4018816B2 (en) |
DE (1) | DE19942897B4 (en) |
GB (1) | GB2341388B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105513B2 (en) * | 2002-08-07 | 2006-09-12 | Sanofi-Avertis Deutschland Gmbh | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3320272A (en) * | 1967-05-16 | Process for preparing z-alkoxycyclo- heptimidazole derivatives | ||
US3084194A (en) * | 1963-04-02 | Preparation of tropones | ||
US2662098A (en) * | 1951-06-04 | 1953-12-08 | Du Pont | Haloalkyl substituted cycloheptatrien-1-ol-2-one ring compounds and methods for their preparation |
US4057556A (en) * | 1976-06-17 | 1977-11-08 | Ayerst, Mckenna & Harrison Ltd. | Troponyl-oxamic acid derivatives |
JPS59134745A (en) * | 1983-09-28 | 1984-08-02 | Masatoshi Yamato | Tropolone derivative having antitumor action |
JPS61215341A (en) * | 1985-03-20 | 1986-09-25 | Masatoshi Yamato | Production of tropolone derivative and use as antitumor agent |
US4749681A (en) * | 1986-05-22 | 1988-06-07 | International Flavors & Fragrances Inc. | Polyalkyl-substituted oxocycloheptane derivatives, organoleptic uses thereof and processes for preparing same |
US5151450A (en) * | 1990-02-22 | 1992-09-29 | Tokyo Tanabe Company, Limited | Antiulcer substance |
JP2707390B2 (en) * | 1992-05-22 | 1998-01-28 | 壽製薬株式会社 | Cycloheptoimidazole derivative, method for producing the same, and drug containing the same |
ZA945190B (en) * | 1993-07-30 | 1995-02-24 | Kotobuki Seiyaku Co Ltd | Carboxymethylidenecycloheptimidazole derivatives method or manufacturing the same and therapeutic agents containing these compounds |
-
1998
- 1998-09-08 JP JP25359598A patent/JP4018816B2/en not_active Expired - Lifetime
-
1999
- 1999-09-08 US US09/391,385 patent/US6278027B1/en not_active Expired - Fee Related
- 1999-09-08 GB GB9921224A patent/GB2341388B/en not_active Expired - Fee Related
- 1999-09-08 DE DE19942897A patent/DE19942897B4/en not_active Expired - Fee Related
-
2001
- 2001-03-14 US US09/805,516 patent/US6316634B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
GB9921224D0 (en) | 1999-11-10 |
JP2000086569A (en) | 2000-03-28 |
DE19942897A1 (en) | 2000-03-09 |
JP4018816B2 (en) | 2007-12-05 |
DE19942897B4 (en) | 2006-12-14 |
US6316634B2 (en) | 2001-11-13 |
GB2341388A (en) | 2000-03-15 |
US6278027B1 (en) | 2001-08-21 |
GB2341388B (en) | 2003-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7750167B2 (en) | Process for the preparation of asenapine and intermediate products used in said process | |
GB2045760A (en) | Process for the preparation of 2,5- bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl) benzamide (flecainide) | |
JP2804558B2 (en) | Method for producing 2-chloro-5-chloromethylpyridine | |
US6316634B2 (en) | Method for preparing cycloheptimidazoles | |
JP2001512091A (en) | Method for producing cyclopropylacetylene | |
JP2543983B2 (en) | Process for producing 4-disubstituted phenyl-1-tetralones | |
JP3663229B2 (en) | Process for producing 4-halo-2'-nitrobutyrophenone compound | |
US6350915B1 (en) | Process for the synthesis of 1-(3,5-bis(trifluoromethyl)-phenyl)ethan-1-one | |
KR100332160B1 (en) | Improved preparation of cycloalkyl and haloalkyl O-aminophenyl ketones | |
JPS629098B2 (en) | ||
HU199798B (en) | Process for producing 2-substituted-5-methyl-pyridine derivatives | |
US6489507B1 (en) | Process for the synthesis of 3,5-bis(trifluoromethyl)benzoic acid | |
JP2586950B2 (en) | Process for producing p- or m-tert-butoxybenzaldehyde | |
US4980489A (en) | 2-(1-alkylaminoalkyl)-3-hydroxy-1,4-naphthoquinone | |
NO20025652L (en) | Process for the preparation of trifluoroethoxy-substituted benzoic acids | |
US5225578A (en) | 2-(1-alkylaminoalkyl)-3-hydroxy-1,4-naphthoquinone, process for its production and processes for producing 2-(1-alkenyl)-3-hydroxy-1,4-naphthoquinone and 2-alkyl-3-acyloxy-1,4-naphthoquinone by using it | |
JP3976286B2 (en) | Method for producing 2-benzoyl-cyclic 1,3-diketone derivative | |
JPH05286882A (en) | Production of 2,3-difluorophenols | |
JP2659587B2 (en) | 4-aziridinyl pyrimidine derivatives and their production | |
US6814895B2 (en) | Process for the synthesis of 1-(3,5-bis(trifluoromethyl)phenyl)ethan-1-one | |
US4215074A (en) | Process for preparing cis-bicyclooctylamines | |
JPH053859B2 (en) | ||
JPH0841005A (en) | Production of 4-fluoroalkoxycynnamonitrile compound | |
JP2833672B2 (en) | Method for producing β-ketonitrile | |
CN114685415A (en) | Synthetic method of kojic acid dimer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
FPAY | Fee payment |
Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20131113 |